THE US Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubriunib) capsules for the treatment of adult patients with a type of non-Hodgkin's lymphoma called mantle cell lymphoma.
Clinical trials of the product showed 84% of patients saw tumour shrinkage with the therapy, which is only approved for people who have received at least one prior therapy.
The FDA's "Breakthrough Therapy" designation sped up Brukinsa's regulatory review.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Nov 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Nov 19